Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.

Related Content

Amgen, Kleiner Perkins Spin-Out Atara Sails Into The Spotlight
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
GSK Takes Rare Diseases Option from Prosensa
Genzyme's Manufacturing Problems
Celgene Partners With Acceleron On Novel Bone Forming Compound





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts